Beta Bionics Inc (NASDAQ: BBNX) is a medical device company that develops and commercializes the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes. Revenue is generated through sales of the iLet device and its components, with reimbursement flowing through third-party payors including commercial insurers and government programs. The company pursues a multi-channel coverage and reimbursement strategy to reach patients. Key performance drivers disclosed in the FY2025 10-K (filed 2026-02-24) include new patient adoption, iLet unit sales volume, third-party payor reimbursement coverage, and continued investment in product development and regulatory approvals. The iLet system consists of a suite of components as described in the FY2025 filing. Beta Bionics operates in the automated insulin delivery segment of the diabetes management market and competes with other device makers in that category, though specific competitors are not named in the available filing excerpts.

Revenue model

Device sales of the iLet Bionic Pancreas and related components, with revenue dependent on third-party payor reimbursement from commercial insurers and government programs. Multi-channel reimbursement strategy disclosed in FY2025 10-K.

Products and services

iLet Bionic Pancreas: an automated insulin delivery system comprising a suite of hardware components for diabetes management. Additional product pipeline initiatives disclosed but not detailed in available excerpts.

Customers and end markets

People with diabetes requiring automated insulin delivery. End market is diabetes management. Reimbursement gatekeepers are third-party payors including commercial and government insurers.

Value-chain role

Medical device manufacturer and direct commercializer of automated insulin delivery systems. Handles manufacturing, quality assurance, regulatory approval, and multi-channel distribution.

Source: SEC 10-K, filed 2026-02-24

Industry: Surgical & Medical Instruments & Apparatus